DRL Announces The Launch Of Anti-Allergy Drug In US Market
Dr. Reddy’s Laboratories Ltd. (DRL) has announced that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of Xyzal Allergy 24HR Tablets, from UCB, in the US market as approved by the US FDA. The drug is an over-the-counter antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes/nose, and sneezing.
“This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,” said Mr. Milan Kalawadia, Vice President and Head, US Over-the-Counter and Speciality Rx businesses, DRL.
The Xyzal Allergy 24HR Tablets brand had US sales of approximately $71-mn for the most recent twelve months ending in January 2018.
You May Interested In
High Quality β-Nicotinamide adenine dinucleotide CAS 53-84-9 NADwith ready stock and best price
$3/UNIT FOB
2026-09-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The United States Lifts Restrictions on Ethane Exports to China, and Trade Relations Show Signs of Easing
-
Biden decided to raise tariffs on Chinese goods, US soybeans maybe face tariff adjustment challenges
-
U.S. agricultural supplies distributor CHS and West Central Ag Services sign merger intent
-
PPG launches strategic review: intends to sell North American architectural coatings business with annual revenue of nearly US$1.8 billion
-
The US chemical industry has had a tough profit season
-
Warm winter impact energy market US coal prices fell rapidly
-
The United States has released its annual update on Salmonella surveillance and testing at poultry producers across the country
-
Allergic rhinitis is back! Experts remind: early prevention and standardized treatment
-
How to Prevent Allergies?
-
Allergics? What Foods to Eat to Prevent Skin Allergies
Recommend Reading
-
![Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders]()
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
![Lilly’s Mounjaro Enters China’s State Insurance System]()
Lilly’s Mounjaro Enters China’s State Insurance System
-
![A New Obesity Pill Enters the Arena With Double-Digit Weight Loss]()
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
![Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown]()
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
![Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November]()
Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November
-
![Business Society’s Urea Trend Analysis for September 16, 2026: Volatile with a Slight Bullish Bias]()
Business Society’s Urea Trend Analysis for September 16, 2026: Volatile with a Slight Bullish Bias
-
![Business Society’s Trend Analysis for Epichlorohydrin on September 15, 2026: Price Trends Are Volatile]()
Business Society’s Trend Analysis for Epichlorohydrin on September 15, 2026: Price Trends Are Volatile
-
![Business Society’s Trend Analysis for Isooctanol on September 16, 2026: Strongly Bullish]()
Business Society’s Trend Analysis for Isooctanol on September 16, 2026: Strongly Bullish
-
![Business Society’s DOP Market Outlook on August 24, 2026: Short-Term Correction]()
Business Society’s DOP Market Outlook on August 24, 2026: Short-Term Correction
-
![Business Society’s Acrylic Acid Trend Analysis for September 16, 2026: Strong Consolidation]()
Business Society’s Acrylic Acid Trend Analysis for September 16, 2026: Strong Consolidation
